{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T05:47:55Z","timestamp":1794030475944,"version":"4.8.0"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T00:00:00Z","timestamp":1724716800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T00:00:00Z","timestamp":1724716800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82022051"],"award-info":[{"award-number":["82022051"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81672883"],"award-info":[{"award-number":["81672883"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82303396"],"award-info":[{"award-number":["82303396"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    While\n                    <jats:italic>KRAS<\/jats:italic>\n                    mutation is the leading cause of low survival rates in lung cancer bone metastasis patients, effective treatments are still lacking. Here, we identified homeobox C10 (HOXC10) as a lynchpin in pan-\n                    <jats:italic>KRAS<\/jats:italic>\n                    -mutant lung cancer bone metastasis. Through RNA-seq approach and patient tissue studies, we demonstrated that HOXC10 expression was dramatically increased. Genetic depletion of\n                    <jats:italic>HOXC10<\/jats:italic>\n                    preferentially impeded cell proliferation and migration in vitro. The bioluminescence imaging and micro-CT results demonstrated that inhibition of\n                    <jats:italic>HOXC10<\/jats:italic>\n                    significantly reduced bone metastasis of\n                    <jats:italic>KRAS<\/jats:italic>\n                    -mutant lung cancer in vivo. Mechanistically, the transcription factor HOXC10 activated NOD1\/ERK signaling pathway to reprogram epithelial-mesenchymal transition (EMT) and bone microenvironment by activating the\n                    <jats:italic>NOD1<\/jats:italic>\n                    promoter. Strikingly, inhibition of\n                    <jats:italic>HOXC10<\/jats:italic>\n                    in combination with STAT3 inhibitor was effective against\n                    <jats:italic>KRAS<\/jats:italic>\n                    -mutant lung cancer bone metastasis by triggering ferroptosis. Taken together, these findings reveal that HOXC10 effectively alleviates pan-\n                    <jats:italic>KRAS<\/jats:italic>\n                    -mutant lung cancer with bone metastasis in the NOD1\/ERK axis-dependent manner, and support further development of an effective combinatorial strategy for this kind of disease.\n                  <\/jats:p>","DOI":"10.1038\/s41413-024-00350-8","type":"journal-article","created":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T06:02:47Z","timestamp":1724738567000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["The HOXC10\/NOD1\/ERK axis drives osteolytic bone metastasis of pan-KRAS-mutant lung cancer"],"prefix":"10.1038","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5863-9865","authenticated-orcid":false,"given":"Kun","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingying","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shihui","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengwang","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyuan","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjie","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangyu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengjuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunpeng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wangjun","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,27]]},"reference":[{"key":"350_CR1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel, R. L., Miller, K. D., Wagle, N. S. & Jemal, A. Cancer statistics, 2023. CA Cancer J. Clin. 73, 17\u201348 (2023).","journal-title":"CA Cancer J. Clin."},{"key":"350_CR2","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1200\/JCO.21.01719","volume":"40","author":"K Jasper","year":"2022","unstructured":"Jasper, K., Stiles, B., McDonald, F. & Palma, D. A. Practical management of oligometastatic non-small-cell lung cancer. J. Clin. Oncol. 40, 635\u2013641 (2022).","journal-title":"J. Clin. Oncol."},{"key":"350_CR3","doi-asserted-by":"publisher","first-page":"8818","DOI":"10.21037\/apm-21-1595","volume":"10","author":"X Huang","year":"2021","unstructured":"Huang, X. et al. Mutational characteristics of bone metastasis of lung cancer. Ann. Palliat. Med. 10, 8818\u20138826 (2021).","journal-title":"Ann. Palliat. Med"},{"key":"350_CR4","doi-asserted-by":"crossref","unstructured":"Del Conte, A. et al. Bone metastasis and immune checkpoint inhibitors in non-small cell lung cancer (NSCLC): Microenvironment and possible clinical implications. Int. J. Mol. Sci. 23 (2022).","DOI":"10.3390\/ijms23126832"},{"key":"350_CR5","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1007\/s12253-015-9955-2","volume":"21","author":"N Bittner","year":"2015","unstructured":"Bittner, N. et al. Bone metastases and the EGFR and KRAS mutation status in lung adenocarcinoma-the results of three year retrospective analysis. Pathol. Oncol. Res. 21, 1217\u20131221 (2015).","journal-title":"Pathol. Oncol. Res."},{"key":"350_CR6","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41568-018-0081-9","volume":"19","author":"NK Altorki","year":"2019","unstructured":"Altorki, N. K. et al. The lung microenvironment: an important regulator of tumour growth and metastasis. Nat. Rev. Cancer 19, 9\u201331 (2019).","journal-title":"Nat. Rev. Cancer"},{"key":"350_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/srep39721","volume":"7","author":"Z Lohinai","year":"2017","unstructured":"Lohinai, Z. et al. KRAS-mutation incidence and prognostic value are metastatic site-specific in lung adenocarcinoma: poor prognosis in patients with KRAS mutation and bone metastasis. Sci. Rep. 7, 39721 (2017).","journal-title":"Sci. Rep."},{"key":"350_CR8","first-page":"3233","volume":"17","author":"J Zhao","year":"2019","unstructured":"Zhao, J., Han, Y., Li, J., Chai, R. & Bai, C. Prognostic value of KRAS\/TP53\/PIK3CA in non-small cell lung cancer. Oncol. Lett. 17, 3233\u20133240 (2019).","journal-title":"Oncol. Lett."},{"key":"350_CR9","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1038\/s41571-022-00671-9","volume":"19","author":"SR Punekar","year":"2022","unstructured":"Punekar, S. R., Velcheti, V., Neel, B. G. & Wong, K. K. The current state of the art and future trends in RAS-targeted cancer therapies. Nat. Rev. Clin. Oncol. 19, 637\u2013655 (2022).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"350_CR10","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-022-01629-2","volume":"21","author":"C Zhu","year":"2022","unstructured":"Zhu, C. et al. Targeting KRAS mutant cancers: from druggable therapy to drug resistance. Mol. Cancer 21, 159 (2022).","journal-title":"Mol. Cancer"},{"key":"350_CR11","doi-asserted-by":"publisher","first-page":"2382","DOI":"10.1056\/NEJMoa2105281","volume":"384","author":"MM Awad","year":"2021","unstructured":"Awad, M. M. et al. Acquired resistance to KRAS(G12C) inhibition in cancer. N. Engl. J. Med. 384, 2382\u20132393 (2021).","journal-title":"N. Engl. J. Med."},{"key":"350_CR12","doi-asserted-by":"crossref","unstructured":"Multiple Mechanisms Underlie the Acquired Resistance to KRAS G12C Inhibition. Cancer Discov. 12, OF7 (2022).","DOI":"10.1158\/2159-8290.CD-RW2022-010"},{"key":"350_CR13","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.684021","volume":"11","author":"J Fang","year":"2021","unstructured":"Fang, J., Wang, J., Yu, L. & Xu, W. Role of HOXC10 in cancer. Front. Oncol. 11, 684021 (2021).","journal-title":"Front. Oncol."},{"key":"350_CR14","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1080\/1061186X.2018.1473408","volume":"27","author":"Y Guan","year":"2019","unstructured":"Guan, Y. et al. Overexpression of HOXC10 promotes glioblastoma cell progression to a poor prognosis via the PI3K\/AKT signalling pathway. J. Drug Target 27, 60\u201366 (2019).","journal-title":"J. Drug Target"},{"key":"350_CR15","doi-asserted-by":"publisher","first-page":"4443","DOI":"10.1158\/0008-5472.CAN-16-0774","volume":"76","author":"H Sadik","year":"2016","unstructured":"Sadik, H. et al. HOXC10 expression supports the development of chemotherapy resistance by fine tuning DNA repair in breast cancer cells. Cancer Res. 76, 4443\u20134456 (2016).","journal-title":"Cancer Res."},{"key":"350_CR16","doi-asserted-by":"publisher","first-page":"572","DOI":"10.21147\/j.issn.1000-9604.2017.06.12","volume":"29","author":"C Guo","year":"2017","unstructured":"Guo, C., Hou, J., Ao, S., Deng, X. & Lyu, G. HOXC10 up-regulation promotes gastric cancer cell proliferation and metastasis through MAPK pathway. Chin. J. Cancer Res. 29, 572\u2013580 (2017).","journal-title":"Chin. J. Cancer Res."},{"key":"350_CR17","first-page":"202","volume":"42","author":"J Kim","year":"2019","unstructured":"Kim, J. et al. HOXC10 overexpression promotes cell proliferation and migration in gastric cancer. Oncol. Rep. 42, 202\u2013212 (2019).","journal-title":"Oncol. Rep."},{"key":"350_CR18","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1007\/s12672-021-00408-7","volume":"12","author":"Y Miao","year":"2021","unstructured":"Miao, Y. et al. HOXC10 promotes growth and migration of melanoma by regulating Slug to activate the YAP\/TAZ signaling pathway. Discov. Oncol. 12, 12 (2021).","journal-title":"Discov. Oncol."},{"key":"350_CR19","doi-asserted-by":"crossref","unstructured":"Xie, Y. et al. Transcription factor HOXC10 activates the expression of MTFR2 to regulate the proliferation, invasion and migration of colorectal cancer cells. Mol. Med. Rep. 24 (2021).","DOI":"10.3892\/mmr.2021.12437"},{"key":"350_CR20","doi-asserted-by":"publisher","first-page":"557","DOI":"10.3389\/fphys.2017.00557","volume":"8","author":"XL Tang","year":"2017","unstructured":"Tang, X. L. et al. HOXC10 promotes the metastasis of human lung adenocarcinoma and indicates poor survival outcome. Front. Physiol. 8, 557 (2017).","journal-title":"Front. Physiol."},{"key":"350_CR21","doi-asserted-by":"publisher","first-page":"16921","DOI":"10.18632\/aging.103597","volume":"12","author":"M Li","year":"2020","unstructured":"Li, M., Alsager, J. S., Wang, Z., Cheng, L. & Shan, B. Epigenetic upregulation of HOXC10 in non-small lung cancer cells. Aging (Albany NY) 12, 16921\u201316935 (2020).","journal-title":"Aging (Albany NY)"},{"key":"350_CR22","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s10555-016-9618-0","volume":"35","author":"HH Popper","year":"2016","unstructured":"Popper, H. H. Progression and metastasis of lung cancer. Cancer Metastasis Rev. 35, 75\u201391 (2016).","journal-title":"Cancer Metastasis Rev."},{"key":"350_CR23","doi-asserted-by":"publisher","first-page":"9705","DOI":"10.7150\/thno.61731","volume":"11","author":"L Mao","year":"2021","unstructured":"Mao, L. et al. Proteomic analysis of lung cancer cells reveals a critical role of BCAT1 in cancer cell metastasis. Theranostics 11, 9705\u20139720 (2021).","journal-title":"Theranostics"},{"key":"350_CR24","doi-asserted-by":"crossref","unstructured":"Zhu, L. et al. Osteoclast-mediated bone resorption is controlled by a compensatory network of secreted and membrane-tethered metalloproteinases. Sci. Transl. Med. 12 (2020).","DOI":"10.1126\/scitranslmed.aaw6143"},{"key":"350_CR25","doi-asserted-by":"publisher","first-page":"3833","DOI":"10.7150\/thno.41712","volume":"10","author":"Y Dang","year":"2020","unstructured":"Dang, Y. et al. Interleukin 1beta-mediated HOXC10 overexpression promotes hepatocellular carcinoma metastasis by upregulating PDPK1 and VASP. Theranostics 10, 3833\u20133848 (2020).","journal-title":"Theranostics"},{"key":"350_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-28452-z","volume":"13","author":"YY Chen","year":"2022","unstructured":"Chen, Y. Y., Ge, J. Y., Zhu, S. Y., Shao, Z. M. & Yu, K. D. Copy number amplification of ENSA promotes the progression of triple-negative breast cancer via cholesterol biosynthesis. Nat. Commun. 13, 791 (2022).","journal-title":"Nat. Commun."},{"key":"350_CR27","doi-asserted-by":"crossref","unstructured":"Velloso, F. J., Trombetta-Lima, M., Anschau, V., Sogayar, M. C. & Correa, R. G. NOD-like receptors: major players (and targets) in the interface between innate immunity and cancer. Biosci. Rep. 39 (2019).","DOI":"10.1042\/BSR20181709"},{"key":"350_CR28","doi-asserted-by":"publisher","first-page":"e0117870","DOI":"10.1371\/journal.pone.0117870","volume":"10","author":"N Castano-Rodriguez","year":"2015","unstructured":"Castano-Rodriguez, N., Kaakoush, N. O., Goh, K. L., Fock, K. M. & Mitchell, H. M. The NOD-like receptor signalling pathway in Helicobacter pylori infection and related gastric cancer: a case-control study and gene expression analyses. PLoS One 10, e0117870 (2015).","journal-title":"PLoS One"},{"key":"350_CR29","doi-asserted-by":"publisher","first-page":"3067","DOI":"10.1084\/jem.20170497","volume":"214","author":"K Hayakawa","year":"2017","unstructured":"Hayakawa, K. et al. NLR Nod1 signaling promotes survival of BCR-engaged mature B cells through up-regulated Nod1 as a positive outcome. J. Exp. Med. 214, 3067\u20133083 (2017).","journal-title":"J. Exp. Med."},{"key":"350_CR30","doi-asserted-by":"publisher","first-page":"e0199350","DOI":"10.1371\/journal.pone.0199350","volume":"13","author":"S Huhn","year":"2018","unstructured":"Huhn, S. et al. Coding variants in NOD-like receptors: an association study on risk and survival of colorectal cancer. PLoS One 13, e0199350 (2018).","journal-title":"PLoS One"},{"key":"350_CR31","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1038\/s41556-019-0309-2","volume":"21","author":"M Esposito","year":"2019","unstructured":"Esposito, M. et al. Bone vascular niche E-selectin induces mesenchymal-epithelial transition and Wnt activation in cancer cells to promote bone metastasis. Nat. Cell Biol. 21, 627\u2013639 (2019).","journal-title":"Nat. Cell Biol."},{"key":"350_CR32","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1158\/0008-5472.CAN-19-2013","volume":"80","author":"B Jing","year":"2020","unstructured":"Jing, B. et al. IL6\/STAT3 signaling orchestrates premetastatic niche formation and immunosuppressive traits in lung. Cancer Res. 80, 784\u2013797 (2020).","journal-title":"Cancer Res."},{"key":"350_CR33","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/j.ccell.2020.06.007","volume":"38","author":"R Siersbaek","year":"2020","unstructured":"Siersbaek, R. et al. IL6\/STAT3 signaling hijacks estrogen receptor alpha enhancers to drive breast cancer metastasis. Cancer Cell 38, 412\u2013423.e419 (2020).","journal-title":"Cancer Cell"},{"key":"350_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-021-03844-z","volume":"12","author":"Z Liu","year":"2021","unstructured":"Liu, Z., Ma, L., Sun, Y., Yu, W. & Wang, X. Targeting STAT3 signaling overcomes gefitinib resistance in non-small cell lung cancer. Cell Death Dis. 12, 561 (2021).","journal-title":"Cell Death Dis."},{"key":"350_CR35","doi-asserted-by":"publisher","first-page":"824","DOI":"10.7150\/thno.49600","volume":"11","author":"Q Zheng","year":"2021","unstructured":"Zheng, Q. et al. A novel STAT3 inhibitor W2014-S regresses human non-small cell lung cancer xenografts and sensitizes EGFR-TKI acquired resistance. Theranostics 11, 824\u2013840 (2021).","journal-title":"Theranostics"},{"key":"350_CR36","doi-asserted-by":"publisher","first-page":"105","DOI":"10.7150\/thno.63788","volume":"12","author":"HJ Lee","year":"2022","unstructured":"Lee, H. J. et al. A novel C-terminal heat shock protein 90 inhibitor that overcomes STAT3-Wnt-beta-catenin signaling-mediated drug resistance and adverse effects. Theranostics 12, 105\u2013125 (2022).","journal-title":"Theranostics"},{"key":"350_CR37","doi-asserted-by":"publisher","first-page":"5701","DOI":"10.1182\/blood-2010-04-280123","volume":"117","author":"MS Redell","year":"2011","unstructured":"Redell, M. S., Ruiz, M. J., Alonzo, T. A., Gerbing, R. B. & Tweardy, D. J. Stat3 signaling in acute myeloid leukemia: ligand-dependent and -independent activation and induction of apoptosis by a novel small-molecule Stat3 inhibitor. Blood 117, 5701\u20135709 (2011).","journal-title":"Blood"},{"key":"350_CR38","doi-asserted-by":"crossref","unstructured":"Verma, N. et al. Synthetic lethal combination targeting BET uncovered intrinsic susceptibility of TNBC to ferroptosis. Sci. Adv. 6 (2020).","DOI":"10.1126\/sciadv.aba8968"},{"key":"350_CR39","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/s41392-020-00428-9","volume":"6","author":"HF Yan","year":"2021","unstructured":"Yan, H. F. et al. Ferroptosis: mechanisms and links with diseases. Signal Transduct. Target Ther. 6, 49 (2021).","journal-title":"Signal Transduct. Target Ther."},{"key":"350_CR40","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.cell.2017.09.021","volume":"171","author":"BR Stockwell","year":"2017","unstructured":"Stockwell, B. R. et al. Ferroptosis: a regulated cell death nexus linking metabolism, redox biology, and disease. Cell 171, 273\u2013285 (2017).","journal-title":"Cell"},{"key":"350_CR41","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1038\/bjc.2017.10","volume":"116","author":"JC Bendell","year":"2017","unstructured":"Bendell, J. C. et al. A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1\/2 inhibitor. Br. J. Cancer 116, 575\u2013583 (2017).","journal-title":"Br. J. Cancer"},{"key":"350_CR42","doi-asserted-by":"publisher","first-page":"2371","DOI":"10.1056\/NEJMoa2103695","volume":"384","author":"F Skoulidis","year":"2021","unstructured":"Skoulidis, F. et al. Sotorasib for Lung Cancers with KRAS p.G12C Mutation. N. Engl. J. Med. 384, 2371\u20132381 (2021).","journal-title":"N. Engl. J. Med."},{"key":"350_CR43","doi-asserted-by":"publisher","first-page":"229ra241","DOI":"10.1126\/scitranslmed.3008326","volume":"6","author":"TN Pathiraja","year":"2014","unstructured":"Pathiraja, T. N. et al. Epigenetic reprogramming of HOXC10 in endocrine-resistant breast cancer. Sci. Transl. Med. 6, 229ra241 (2014).","journal-title":"Sci. Transl. Med."},{"key":"350_CR44","doi-asserted-by":"publisher","first-page":"10163","DOI":"10.1158\/0008-5472.CAN-07-2056","volume":"67","author":"Y Zhai","year":"2007","unstructured":"Zhai, Y. et al. Gene expression analysis of preinvasive and invasive cervical squamous cell carcinomas identifies HOXC10 as a key mediator of invasion. Cancer Res. 67, 10163\u201310172 (2007).","journal-title":"Cancer Res"},{"key":"350_CR45","doi-asserted-by":"publisher","first-page":"19375","DOI":"10.18632\/aging.103824","volume":"12","author":"Y Peng","year":"2020","unstructured":"Peng, Y. et al. HOXC10 promotes tumour metastasis by regulating the EMT-related gene Slug in ovarian cancer. Aging (Albany NY) 12, 19375\u201319398 (2020).","journal-title":"Aging (Albany NY)"},{"key":"350_CR46","doi-asserted-by":"publisher","first-page":"4540","DOI":"10.7150\/jca.30645","volume":"10","author":"BW Dai","year":"2019","unstructured":"Dai, B. W. et al. HOXC10 promotes migration and invasion via the WNT-EMT signaling pathway in oral squamous cell carcinoma. J. Cancer 10, 4540\u20134551 (2019).","journal-title":"J. Cancer"},{"key":"350_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.mcp.2019.101491","volume":"49","author":"M Ma","year":"2020","unstructured":"Ma, M. et al. HOXC10 promotes proliferation and attenuates lipid accumulation of sheep bone marrow mesenchymal stem cells. Mol. Cell Probes 49, 101491 (2020).","journal-title":"Mol. Cell Probes"},{"key":"350_CR48","doi-asserted-by":"publisher","first-page":"5441","DOI":"10.1038\/s41388-020-1375-4","volume":"39","author":"D Suo","year":"2020","unstructured":"Suo, D. et al. HOXC10 upregulation confers resistance to chemoradiotherapy in ESCC tumor cells and predicts poor prognosis. Oncogene 39, 5441\u20135454 (2020).","journal-title":"Oncogene"},{"key":"350_CR49","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1038\/s41392-021-00780-4","volume":"6","author":"L Huang","year":"2021","unstructured":"Huang, L., Guo, Z., Wang, F. & Fu, L. KRAS mutation: from undruggable to druggable in cancer. Signal Transduct. Target Ther. 6, 386 (2021).","journal-title":"Signal Transduct. Target Ther."},{"key":"350_CR50","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms4511","volume":"5","author":"F Lamoureux","year":"2014","unstructured":"Lamoureux, F. et al. Selective inhibition of BET bromodomain epigenetic signalling interferes with the bone-associated tumour vicious cycle. Nat. Commun. 5, 3511 (2014).","journal-title":"Nat. Commun."},{"key":"350_CR51","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/j.ccell.2020.03.004","volume":"37","author":"SL Guerra","year":"2020","unstructured":"Guerra, S. L. et al. A deregulated HOX gene axis confers an epigenetic vulnerability in KRAS-mutant lung cancers. Cancer Cell 37, 705\u2013719.e706 (2020).","journal-title":"Cancer Cell"},{"key":"350_CR52","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1016\/j.bbrc.2018.05.019","volume":"501","author":"S Yao","year":"2018","unstructured":"Yao, S. et al. HOXC10 promotes gastric cancer cell invasion and migration via regulation of the NF-kappaB pathway. Biochem. Biophys. Res. Commun. 501, 628\u2013635 (2018).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"350_CR53","doi-asserted-by":"publisher","DOI":"10.1002\/jev2.12264","volume":"11","author":"X Wei","year":"2022","unstructured":"Wei, X. et al. Extracellular vesicles from colorectal cancer cells promote metastasis via the NOD1 signalling pathway. J. Extracell. Vesicles 11, e12264 (2022).","journal-title":"J. Extracell. Vesicles"},{"key":"350_CR54","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1101\/gad.311852.118","volume":"32","author":"S D\u2019Amico","year":"2018","unstructured":"D\u2019Amico, S. et al. STAT3 is a master regulator of epithelial identity and KRAS-driven tumorigenesis. Genes Dev. 32, 1175\u20131187 (2018).","journal-title":"Genes Dev."},{"key":"350_CR55","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms7285","volume":"6","author":"B Grabner","year":"2015","unstructured":"Grabner, B. et al. Disruption of STAT3 signalling promotes KRAS-induced lung tumorigenesis. Nat. Commun. 6, 6285 (2015).","journal-title":"Nat. Commun."},{"key":"350_CR56","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2022.102317","volume":"52","author":"S Ouyang","year":"2022","unstructured":"Ouyang, S. et al. Inhibition of STAT3-ferroptosis negative regulatory axis suppresses tumor growth and alleviates chemoresistance in gastric cancer. Redox Biol. 52, 102317 (2022).","journal-title":"Redox Biol."},{"key":"350_CR57","doi-asserted-by":"publisher","first-page":"6235","DOI":"10.1158\/0008-5472.CAN-18-0634","volume":"78","author":"NS Nagathihalli","year":"2018","unstructured":"Nagathihalli, N. S. et al. Inverse correlation of STAT3 and MEK signaling mediates resistance to RAS pathway inhibition in pancreatic cancer. Cancer Res. 78, 6235\u20136246 (2018).","journal-title":"Cancer Res"},{"key":"350_CR58","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1172\/JCI124049","volume":"130","author":"K Hu","year":"2020","unstructured":"Hu, K. et al. Suppression of the SLC7A11\/glutathione axis causes synthetic lethality in KRAS-mutant lung adenocarcinoma. J. Clin. Invest. 130, 1752\u20131766 (2020).","journal-title":"J. Clin. Invest."},{"key":"350_CR59","doi-asserted-by":"crossref","unstructured":"Li, K. et al. BCL6 is regulated by the MAPK\/ELK1 axis and promotes KRAS-driven lung cancer. J. Clin. Invest. 132 (2022).","DOI":"10.1172\/JCI161308"},{"key":"350_CR60","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1038\/nmeth.2956","volume":"11","author":"Y Zhu","year":"2014","unstructured":"Zhu, Y., Qiu, P. & Ji, Y. TCGA-assembler: open-source software for retrieving and processing TCGA data. Nat. Methods 11, 599\u2013600 (2014).","journal-title":"Nat. Methods"},{"key":"350_CR61","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-12108-6","volume":"10","author":"R Romero-Moreno","year":"2019","unstructured":"Romero-Moreno, R. et al. The CXCL5\/CXCR2 axis is sufficient to promote breast cancer colonization during bone metastasis. Nat. Commun. 10, 4404 (2019).","journal-title":"Nat. Commun."},{"key":"350_CR62","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1016\/j.ccell.2020.08.002","volume":"38","author":"C Li","year":"2020","unstructured":"Li, C. et al. Integrated Omics of Metastatic Colorectal Cancer. Cancer Cell 38, 734\u2013747.e739 (2020).","journal-title":"Cancer Cell"}],"container-title":["Bone Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41413-024-00350-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41413-024-00350-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41413-024-00350-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T06:02:55Z","timestamp":1724738575000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41413-024-00350-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,27]]},"references-count":62,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["350"],"URL":"https:\/\/doi.org\/10.1038\/s41413-024-00350-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3720283\/v1","asserted-by":"object"}]},"ISSN":["2095-6231"],"issn-type":[{"value":"2095-6231","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,27]]},"assertion":[{"value":"7 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"47"}}